Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;26(6):767-785.
doi: 10.1007/s40272-024-00657-3. Epub 2024 Oct 5.

Adverse Event Profile of First-line Drugs for Treating Patent Ductus Arteriosus in Neonates: A Disproportionality Analysis Study of USFDA Adverse Event Reporting System

Kannan Sridharan  1 , Gowri Sivaramakrishnan  2
Affiliations

Adverse Event Profile of First-line Drugs for Treating Patent Ductus Arteriosus in Neonates: A Disproportionality Analysis Study of USFDA Adverse Event Reporting System

Kannan Sridharan et al. Paediatr Drugs. 2024 Nov.

Abstract

Background: Acetaminophen, ibuprofen, and indomethacin are widely used as first-line drugs for patent ductus arteriosus (PDA) closure in preterm neonates. However, their relative safety profiles remain unclear.

Methods: Adverse event reports related to the first-line drugs used in PDA and neonates in general were retrieved from the US Food and Drug Authority (FDA) Adverse Event Reporting System. Deduplicated reports were analyzed using proportional reporting ratios and reporting odds ratios to identify disproportionality safety signals between drugs.

Results: A total of 969 unique reports related to the first-line drugs used in PDA and 499 reports in the neonatal period were included. Acetaminophen signals primarily involved the liver, while ibuprofen and indomethacin signals pertained to gastrointestinal, renal, vascular, and mortality outcomes. Higher occurrences of death were reported with indomethacin and ibuprofen compared with acetaminophen.

Conclusion: This first comparison of PDA drug safety profiles from spontaneous reports highlights some differences, with acetaminophen potentially conferring a safer adverse effect profile overall. While limitations include missing data and reporting biases, the signals warrant further validation. Given its comparable efficacy to ibuprofen, as demonstrated in other studies, acetaminophen has the potential to be preferred as an initial medical therapy for PDA.

PubMed Disclaimer

References

    1. Sellmer A, Bjerre JV, Schmidt MR, McNamara PJ, Hjortdal VE, Høst B, Bech BH, Henriksen TB. Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3. Arch Dis Child Fetal Neonatal Ed. 2013;98(6):F505–10. - DOI - PubMed
    1. Backes CH, Hill KD, Shelton EL, Slaughter JL, Lewis TR, Weisz DE, Mah ML, Bhombal S, Smith CV, McNamara PJ, Benitz WE, Garg V. Patent ductus arteriosus: a contemporary perspective for the pediatric and adult cardiac care provider. J Am Heart Assoc. 2022;11(17): e025784. - DOI - PubMed - PMC
    1. Park J, Yoon SJ, Han J, Song IG, Lim J, Shin JE, Eun HS, Park KI, Park MS, Lee SM. Patent ductus arteriosus treatment trends and associated morbidities in neonates. Sci Rep. 2021;11(1):10689. - DOI - PubMed - PMC
    1. Eursiriwan S, Okascharoen C, Vallibhakara SA, Pattanaprateep O, Numthavaj P, Attia J, Thakkinstian A. Comparison of various pharmacologic agents in the management of hemodynamically significant patent ductus arteriosus in preterm: a network meta-analysis and risk-benefit analysis. Biomed Hub. 2022;7(3):125–45. - DOI - PubMed - PMC
    1. Marconi E, Bettiol A, Ambrosio G, Perduca V, Vannacci A, Troiani S, Dani C, Mugelli A, Lucenteforte E. Efficacy and safety of pharmacological treatments for patent ductus arteriosus closure: a systematic review and network meta-analysis of clinical trials and observational studies. Pharmacol Res. 2019;148: 104418. - DOI - PubMed

MeSH terms

LinkOut - more resources